Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.1
(0.99%)
CNY 5.1
(0.99%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.72 Billion CNY | -14.94% |
| 2022 | 6.73 Billion CNY | 59.08% |
| 2021 | 4.23 Billion CNY | 48.11% |
| 2020 | 2.85 Billion CNY | 120.28% |
| 2019 | 1.29 Billion CNY | 9.15% |
| 2018 | 1.18 Billion CNY | 11.09% |
| 2017 | 1.06 Billion CNY | 84.69% |
| 2016 | 579.15 Million CNY | 17.28% |
| 2015 | 493.82 Million CNY | 28.05% |
| 2014 | 385.66 Million CNY | 42.3% |
| 2013 | 271.02 Million CNY | 60.13% |
| 2012 | 169.24 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5.42 Billion CNY | -1.91% |
| 2024 Q3 | 5.09 Billion CNY | -6.07% |
| 2024 Q1 | 5.52 Billion CNY | -3.45% |
| 2023 Q3 | 6.09 Billion CNY | -1.21% |
| 2023 Q4 | 5.72 Billion CNY | -6.06% |
| 2023 FY | 5.72 Billion CNY | -14.94% |
| 2023 Q1 | 6.44 Billion CNY | -4.3% |
| 2023 Q2 | 6.17 Billion CNY | -4.22% |
| 2022 Q4 | 6.73 Billion CNY | 5.18% |
| 2022 FY | 6.73 Billion CNY | 59.08% |
| 2022 Q1 | 5.13 Billion CNY | 21.41% |
| 2022 Q2 | 5.79 Billion CNY | 12.89% |
| 2022 Q3 | 6.39 Billion CNY | 10.34% |
| 2021 Q3 | 3.94 Billion CNY | 11.37% |
| 2021 Q2 | 3.54 Billion CNY | 9.75% |
| 2021 Q4 | 4.23 Billion CNY | 7.2% |
| 2021 FY | 4.23 Billion CNY | 48.11% |
| 2021 Q1 | 3.22 Billion CNY | 13.03% |
| 2020 Q1 | 1.38 Billion CNY | 6.48% |
| 2020 Q4 | 2.85 Billion CNY | 4.3% |
| 2020 FY | 2.85 Billion CNY | 120.28% |
| 2020 Q2 | 1.54 Billion CNY | 11.91% |
| 2020 Q3 | 2.73 Billion CNY | 77.23% |
| 2019 Q1 | 1.18 Billion CNY | 0.07% |
| 2019 FY | 1.29 Billion CNY | 9.15% |
| 2019 Q3 | 1.23 Billion CNY | 4.06% |
| 2019 Q4 | 1.29 Billion CNY | 4.62% |
| 2019 Q2 | 1.19 Billion CNY | 0.19% |
| 2018 FY | 1.18 Billion CNY | 11.09% |
| 2018 Q4 | 1.18 Billion CNY | 1.63% |
| 2018 Q3 | 1.16 Billion CNY | -1.29% |
| 2018 Q2 | 1.18 Billion CNY | 2.94% |
| 2018 Q1 | 1.15 Billion CNY | 7.57% |
| 2017 Q3 | 1.02 Billion CNY | 3.14% |
| 2017 Q4 | 1.06 Billion CNY | 4.4% |
| 2017 FY | 1.06 Billion CNY | 84.69% |
| 2017 Q1 | 560.88 Million CNY | -3.15% |
| 2017 Q2 | 993.37 Million CNY | 77.11% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q2 | 536.87 Million CNY | 0.0% |
| 2016 Q4 | 579.15 Million CNY | 0.0% |
| 2016 FY | 579.15 Million CNY | 17.28% |
| 2015 FY | 493.82 Million CNY | 28.05% |
| 2014 FY | 385.66 Million CNY | 42.3% |
| 2013 FY | 271.02 Million CNY | 60.13% |
| 2012 FY | 169.24 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 17.93 Billion CNY | 68.082% |
| Hangzhou Tigermed Consulting Co., Ltd. | 29.69 Billion CNY | 80.72% |
| Dirui Industrial Co.,Ltd. | 3.32 Billion CNY | -72.424% |
| Beijing Strong Biotechnologies, Inc. | 5.17 Billion CNY | -10.627% |
| Medicalsystem Biotechnology Co., Ltd. | 3.48 Billion CNY | -64.101% |
| Maccura Biotechnology Co.Ltd | 8.11 Billion CNY | 29.479% |
| Guangzhou Wondfo Biotech Co.,Ltd | 5.77 Billion CNY | 0.796% |
| BGI Genomics Co., Ltd. | 13.61 Billion CNY | 57.939% |
| Amoy Diagnostics Co., Ltd. | 1.93 Billion CNY | -195.925% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 2.98 Billion CNY | -91.699% |